Semaglutide
In the tracked data, 30 of 30 EU+ jurisdictions list authorised or limited status for Semaglutide. This page summarises approval status, brands, shortages and recent regulatory changes by country.
Related regulatory compounds
Country-by-country approval and availability
30 EU+ jurisdictions covered.
Updates for Semaglutide
2026-07-15 · 🇪🇺 EU
EU approval: Wegovy pill (oral semaglutide)
15 July 2026: the European Commission approved the Wegovy pill (oral semaglutide) as the first oral GLP-1 receptor agonist for weight management in the EU. A single ready-to-use 7.2 mg higher-dose pen was approved at the same time.
2026-05-21 · 🇪🇺 EU
CHMP: positive opinion for oral Wegovy (semaglutide)
21 May 2026: EMA's CHMP adopted a positive opinion for a new pharmaceutical form of Wegovy — oral tablets (1.5 / 4 / 9 / 25 mg) for weight management. The first oral GLP-1 receptor agonist for this indication. In the OASIS 4 trial, 25 mg once daily showed 16.6% mean weight loss.
2026-03-26 · 🇪🇺 EU
EMA CHMP March 2026: 5 new medicines + 13 indication extensions
At the 23-26 March 2026 meeting, EMA's CHMP recommended approval of 5 new medicines and 13 extensions of therapeutic indications for existing marketing authorisations — including metabolic/endocrine indications.
2026-02-15 · 🇬🇧 United Kingdom
NICE NG28: widened access to GLP-1s & SGLT-2 inhibitors for T2D
February 2026: NICE updated guideline NG28 on type 2 diabetes management in adults, widening access to GLP-1 receptor agonists (liraglutide, dulaglutide, semaglutide up to 1mg/week) and SGLT-2 inhibitors. Estimated to prevent up to 17,000 deaths in the UK over 3 years.
2026-01-29 · 🇪🇺 EU
EMA CHMP January 2026: 6 new approvals + 9 extensions
At the 26-29 January 2026 meeting, CHMP recommended 6 new medicine approvals and 9 indication extensions — the first major EMA-level regulatory decision of 2026.
2025-09-03 · 🇪🇺 EU
EMA warning: sharp rise in illegal GLP-1 medicines sold in the EU
EMA and the HMA issued a joint warning about illegal medicines sold as GLP-1 receptor agonists for weight loss and diabetes, posing serious health risks.
2025-03-21 · 🇪🇺 EU
FDA: semaglutide & tirzepatide shortages officially resolved — stricter compounding rules
FDA confirmed that semaglutide and tirzepatide shortages are officially resolved, triggering restrictions on 503A/503B pharmacy compounding in the US — with downstream effects on the global market.
2024-12-01 · France
Wegovy®: Sécurité Sociale coverage expanded
Reimbursement extended to patients with BMI ≥35 and comorbidity.
2024-11-20 · 🇪🇺 EU
EMA notice: prolonged Ozempic® shortage
EMA confirmed ongoing shortage until Q2 2025 across 0.25mg, 0.5mg and 1mg pens.
2024-06-18 · 🇵🇱 Poland
URPL: severe Ozempic® shortage in Poland
URPL recorded widespread shortage leading to T2D prescription rationing.